8-K 1 v086932_8k.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
 
Washington D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
 
PURSUANT TO SECTION 13 OR 15(D)
 
OF THE SECURITIES EXCHANGE ACT OF 1934
 
Date of Report (Date of earliest event reported)
 
September 4, 2007
 
AURIGA LABORATORIES, INC.
 
(Exact name of registrant as specified in its charter)
 
Delaware
000-26013
84-1334687
(State of incorporation)
(Commission File Number)
(I.R.S. Employer
Identification No.)
     
10635 Santa Monica Blvd. #120
Los Angeles, California
 
90025
(Address of principal executive offices)
(Zip Code)
   
(310) 461-3600
(Registrant’s telephone number, including area code)
 
Not Applicable
(Former name or former address, if changed since last report)
 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 

 
 
 

SECTION 8—OTHER EVENTS
 
Item 8.01. Other Items
 
On September 4, 2007, Auriga Laboratories, Inc. (the “Company”) issued a press release announcing that Andrew Shales, the Company’s Chief Operating Officer and Alan Roberts, the Company’s Chief Scientific Officer, have terminated their pre-arranged stock trading plans. Mr. Shales & Mr. Roberts stock plans were terminated effective immediately. These stock trading plans had previously been adopted pursuant to Securities and Exchange Commission Rule 10b5-1. A copy of that press release is furnished as an exhibit to this report as Exhibit 99.1 and is incorporated herein by reference.
 
The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to liability under such section, nor shall it be deemed incorporated by reference in any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing, unless expressly incorporated by specific reference in such filing. The Company has posted a copy of this Current Report on Form 8-K on its website at www.aurigalabs.com.
 
Item 9.01. Financial Statements and Exhibits.
 
(d) Exhibits. The following exhibits are filed herewith:
 
Exhibit Number
Document
 
 
99.1
 
 
Press Release of Auriga Laboratories, Inc. dated September 4, 2007.
 
   

 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 

 
 
Auriga Laboratories, Inc.
 
 
Date: September 4, 2007
 
By:   /s/ Philip S. Pesin
Philip S. Pesin
Chief Executive Officer
   
   

 
 
2